Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis

Wonji Kim, Krinio Giannikou, John R. Dreier, Sanghun Lee, Magdalena E. Tyburczy, Edwin K. Silverman, Elżbieta Radzikowska, Shulin Wu, Chin-Lee Wu, Elizabeth P. Henske, Gary Hunninghake, Havi Carel, Antonio Roman, Miquel Angel Pujana, Joel Moss, Sungho Won, David J. Kwiatkowski
European Respiratory Journal 2019 53: 1900329; DOI: 10.1183/13993003.00329-2019
Wonji Kim
1Interdisciplinary Program of Bioinformatics, Seoul National University, Seoul, Korea
2Channing Division of Network Medicine, Dept of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
13These two authors contributed equally to this work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wonji Kim
Krinio Giannikou
3Division of Pulmonary and Critical Care Medicine and of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
13These two authors contributed equally to this work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. Dreier
3Division of Pulmonary and Critical Care Medicine and of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanghun Lee
4Dept of Medical Consilience, Graduate School, Dankook University, Yongin-si, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena E. Tyburczy
3Division of Pulmonary and Critical Care Medicine and of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin K. Silverman
2Channing Division of Network Medicine, Dept of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
3Division of Pulmonary and Critical Care Medicine and of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elżbieta Radzikowska
5National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shulin Wu
6Urology Research Laboratory, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chin-Lee Wu
6Urology Research Laboratory, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth P. Henske
3Division of Pulmonary and Critical Care Medicine and of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Hunninghake
3Division of Pulmonary and Critical Care Medicine and of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Havi Carel
7Dept of Philosophy, University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Roman
8Vall d'Hebron University Hospital, CIBERES, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miquel Angel Pujana
9ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute of Biomedical Research (IDIBELL), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Moss
10Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sungho Won
11Dept of Public Health Sciences, Seoul National University, Seoul, Korea
12Institute of Health and Environment, Seoul National University, Seoul, Korea
14Joint senior authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Kwiatkowski
3Division of Pulmonary and Critical Care Medicine and of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
14Joint senior authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dk@rics.bwh.harvard.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction Lymphangioleiomyomatosis (LAM) occurs either associated with tuberous sclerosis complex (TSC) or as sporadic disease (S-LAM). Risk factors for development of S-LAM are unknown. We hypothesised that DNA sequence variants outside of TSC2/TSC1 might be associated with susceptibility for S-LAM and performed a genome-wide association study (GWAS).

Methods Genotyped and imputed data on 5 426 936 single nucleotide polymorphisms (SNPs) in 426 S-LAM subjects were compared, using conditional logistic regression, with similar data from 852 females from COPDGene in a matched case–control design. For replication studies, genotypes for 196 non-Hispanic White female S-LAM subjects were compared with three different sets of controls. RNA sequencing and immunohistochemistry analyses were also performed.

Results Two noncoding genotyped SNPs met genome-wide significance: rs4544201 and rs2006950 (p=4.2×10−8 and 6.1×10−9, respectively), which are in the same 35 kb linkage disequilibrium block on chromosome 15q26.2. This association was replicated in an independent cohort. NR2F2 (nuclear receptor subfamily 2 group F member 2), a nuclear receptor and transcription factor, was the only nearby protein-coding gene. NR2F2 expression was higher by RNA sequencing in one abdominal LAM tumour and four kidney angiomyolipomas, a LAM-related tumour, compared with all cancers from The Cancer Genome Atlas. Immunohistochemistry showed strong nuclear expression in both LAM and angiomyolipoma tumours.

Conclusions SNPs on chromosome 15q26.2 are associated with S-LAM, and chromatin and expression data suggest that this association may occur through effects on NR2F2 expression, which potentially plays an important role in S-LAM development.

Abstract

GWAS identified alleles of two SNPs near NR2F2 that were associated with sporadic lymphangioleiomyomatosis. NR2F2 is a transcription factor that is expressed highly in both LAM and a LAM-related tumour, and NR2F2 is a new LAM gene. http://ow.ly/87xx30oiVhZ

Introduction

Lymphangioleiomyomatosis (LAM) is a rare aggressive low-grade neoplasm which affects almost exclusively females at reproductive age or older and causes progressive cystic lung destruction leading to fatal respiratory failure in subjects with severe disease [1–6]. LAM is characterised by an abnormal proliferation of smooth muscle-like and epithelioid cells in innumerable tiny clusters in the lungs, in association with thin-walled cysts and lung parenchymal destruction [7, 8]. Progressive cyst enlargement and inflammation contribute to decline in lung function measured as both decreased forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide. The diagnosis of LAM is based on clinical features, chest computed tomography findings of thin-walled cysts and either pathology seen on lung biopsy or elevated serum vascular endothelial growth factor (VEGF)-D levels.

LAM occurs at high frequency (>10%) in females with tuberous sclerosis complex (TSC) and at much lower frequency in females (∼1 in 100 000) without that disorder, in which it is called sporadic (S)-LAM. TSC is due to germline and/or mosaic mutations in either TSC1 (25%) or TSC2 (75%) [9]. Tumour development in TSC follows the classic Knudson model of a germline mutation complemented by a somatic second-hit mutation in the other corresponding allele in tumours [9, 10]. Limited data are available for S-LAM, but it appears that TSC2 mutations are seen in the vast majority of S-LAM lesions. About 50% of S-LAM subjects have kidney angiomyolipoma, a tumour which is seen in 70–80% of adults with TSC. Angiomyolipoma shares histological, expression and genetic features with LAM, although the lesions are not pathologically identical.

Genome-wide association studies (GWASs) are utilised to identify genetic variants and susceptibility loci associated with complex traits and common diseases. Although there is no precedent for genetic influence on the development of S-LAM, we hypothesised that DNA sequence variants outside of TSC2/TSC1 might be associated with disease risk and go unrecognised due to the low prevalence of this disorder.

Methods

Discovery cohort

Over 600 female S-LAM patients were initially identified and collected through international solicitation during 2010–2014 from 14 countries (supplementary table S1). S-LAM patients were diagnosed using standard diagnostic criteria by their treating physicians [1–5, 7]. Genomic DNA was extracted from saliva using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and 479 S-LAM DNA samples were genotyped with the Infinium OmniExpress-24 version 1.2 BeadChip (Illumina, San Diego, CA, USA), which assesses 716 503 single nucleotide polymorphisms (SNPs) across the entire genome. 34 non-White S-LAM subjects were excluded from further analyses. There were no self-declared Hispanics in this set of subjects.

Genotype data from the same genotyping chip were available for 1261 healthy female volunteers from the COPDGene consortium and were obtained from dbGaP (www.ncbi.nlm.nih.gov/gap; phs000951.v2.p2.c1). These COPDGene participants had smoked at least 10 pack-years and were 45–80 years old, and were without known chronic obstructive pulmonary disease [11].

Quality control analyses of SNP genotype data

We evaluated the quality of SNPs and subjects in the discovery dataset using PLINK [12] and ONETOOL [13]. We excluded all SNPs for which the Hardy–Weinberg equilibrium test [14] gave p<1×10−5, minor allele frequency (MAF) was <0.05 or genotype call rates were <95%. We also discarded any subjects whose missing genotype rates were >5% or showed identity-by-state >80% with any other subject (figure 1). These filtering procedures were first applied separately to both cases and controls, and were repeated on the pooled dataset. In addition, any SNP showing a difference in missing data rate between cases and controls by Fisher's exact test [15] with p<1×10−5 was removed (figure 1).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Workflow of statistical analysis and quality control for the lymphangioleiomyomatosis (LAM) genome-wide association study discovery dataset. SNP: single nucleotide polymorphism; HWE: Hardy–Weinberg equilibrium; MAF: minor allele frequency; IBS: identity-by-state. Multiple standard quality controls were performed for both cases (sporadic (S)-LAM subjects) and controls (healthy females without chronic obstructive pulmonary disease from the COPDGene consortium) to exclude outlier SNPs and subjects.

Genome-wide imputation

We performed genome-wide imputation for all autosomes to enable discovery of associations for both genotyped and imputed SNPs. Imputation was conducted using the Sanger Imputation Service (https://imputation.sanger.ac.uk). We used Haplotype Reference Consortium release version 1.1 for the reference panel and considered predominantly European ancestry [16]. Pre-phasing was performed first with Eagle2 version 2.0.5 [17] and then the PBWT (Positional Burrows–Wheeler Transform) package [18] used for imputation according to the imputation pipeline recommended by the Sanger Imputation Service. Imputation accuracy was evaluated with the INFO metric [19]. Imputed SNPs were filtered out if INFOs, MAFs or p-values for the Hardy–Weinberg equilibrium test were <0.3, <0.05 or <1×10−5, respectively.

Statistical analyses with genetic data

EIGENSTRAT [20] was also applied to the pooled data and principal component (PC) scores were calculated. PC scores were used to detect subjects with an outlying genetic background and such outliers (three subjects) were then removed (figure 1).

To ensure matching of cases and controls for primary analysis, we used conditional logistic regression (CLR). Each case was matched with two controls using the R package Matching [21]. Matching quality is affected by the number of PC scores used and we assessed how many PC scores were required for effective matching. Two PC scores gave the genomic inflation factor closest to 1 (supplementary figure S1). Thus, CLR was conducted by conditioning on the matched cases and controls with the first two PC scores. Our CLR can be expressed as follows.

For the ith strata: Embedded Image where Yij and Xij indicate the phenotype and covariates including SNPs of the jth subject in the ith matched strata, respectively. For covariates, 10 PC scores were included to adjust the additional population substructure. CLR analyses were performed with the R package survival [22] and genome-wide significance was assessed by p<5×10−8.

We applied the PICS software to all imputed and genotyped SNPs showing association with LAM to calculate the probability of each individual SNP being the causal SNP [23].

We also conducted gene-based analyses for association with LAM for those genes near the genome-wide significant SNPs using the SKAT-O statistic [24]. We included all genotyped SNPs in this analysis with no MAF cut-off for inclusion. Age, age squared and 10 PC scores were included as covariates.

Replication data

Replication analysis was done on an independent set of 196 non-Hispanic White female S-LAM subjects, seen at the NIH Clinical Centre (Bethesda, MD, USA) by one co-author (J.M.) (supplementary table S1). Careful scrutiny was performed by a third independent party (“honest broker”) to compare the names of subjects used in the primary analysis and patient candidates for the replication population to select those that were not analysed in the primary analysis. Genotyping was performed by TaqMan SNP genotyping assays C_832391_10 and C_27296040_10 for SNPs rs2006950 and rs4544201, respectively (Thermo Fisher Scientific, Waltham, MA, USA). Nine randomly selected S-LAM subjects from the discovery study were also genotyped by this method to confirm genotyping accuracy in the replication analysis. Their discovery study genotypes matched the TaqMan analysis genotypes perfectly and these nine subjects were not included in the replication analyses. We used three independent datasets as controls for comparison in the replication study: 1) 409 non-Hispanic White healthy females from the COPDGene consortium who were not used for discovery analyses, 2) 1121 Hispanic White females in the Multi-Ethnic Study of Atherosclerosis (MESA) dataset obtained from dbGaP (phs000209.v13.p3) [25] and 3) 225 731 British White females from the UK Biobank dataset [26]. For each control dataset, we used genotyped or imputed data for the genome-wide significant SNPs.

Topologically associated domains and chromatin interactions

To identify chromatin interactions in the region of interest on chromosome 15q26.2, we used two three-dimensional genome browsers (www.3dgenome.org and https://yunliweb.its.unc.edu/hugin) to predict topologically associated domains (TADs) [27, 28]. We checked for TADs around the genome-wide significant SNPs and protein-coding genes belonging to each TAD were investigated. We analysed TADs from four cell lines/tissues judged closest to LAM: 1) human fetal lung fibroblasts (IMR90), 2) lung-related tissues, 3) H1-derived mesenchymal stem cells (H1-MSCs) and 4) human umbilical vein endothelial cells (HUVECs).

Statistical analyses with RNA sequencing data

Whole transcriptome RNA sequencing analysis was performed on one abdominal LAM tumour and four kidney angiomyolipomas at the Broad Institute of Harvard and MIT (Boston, MA, USA). Briefly, mRNA sequencing was performed using poly(A) cDNA capture followed by cDNA library synthesis (Truseq RNA Library Prep Kit; Illumina) and sequencing on Illumina machines, following the same methods and in the same facility in which the Gene and Tissue Expression (GTEx) RNA sequencing project occurred [29]. Read data were processed into FASTQ files with standard quality control methods and aligned to the genome (Genome Reference Consortium GRCh37 (hg19)) using TopHat version 2.0.10 [30]. FASTQ files were also converted into RSEM (RNA sequencing by expectation maximisation) format [31]. RSEM values were compared with RNA sequencing data from 2463 tumours of 27 different histological types from The Cancer Genome Atlas (TCGA) [32]. RPKM (reads per kilobase per million mapped reads) values for NR2F2 (nuclear receptor subfamily 2 group F member 2) were compared with the GTEx dataset of normal human tissues with the limma statistic (11 688 RNA sequencing samples from 53 normal tissue types, version 7 release) [29].

We also searched for any cis-expression quantitative trait loci (eQTL) for all SNPs in the linkage disequilibrium block with association to LAM using the GTEx release version 7 database [29]. This resource provides results of eQTL analysis for each SNP–gene pair for all SNPs within 1 Mb upstream and downstream of the transcription start site. FastQTL is used by this resource (www.gtexportal.org/home) for cis-eQTL mapping [33] with covariate adjustment of the top three PC scores, genotyping platform, sex and a set of relevant variables identified using the PEER method [34].

Immunohistochemistry analyses

Immunohistochemistry was performed as described elsewhere [35] using a primary mouse monoclonal antibody against NR2F2 (ab41859; Abcam, Cambridge, MA, USA; concentration 1:100 (10 μg·mL−1)). Briefly, formalin-fixed, paraffin-embedded tumour sections were deparaffinised in xylene, rehydrated and antigen retrieval was performed in EDTA (pH 8.0) (Diagnostic BioSystems, Pleasanton, CA, USA). Endogenous peroxidase activity was blocked with 3% hydrogen peroxide; blocking was done with 5% goat serum, followed by incubation overnight with antibody at 4°C, washing in TBS/Tween 20 and incubation with anti-goat secondary antibody (Vector, Burlingame, CA, USA; dilution 1:300). The peroxidase reaction was developed using 3,3ʹ-diaminobenzidine substrate (DakoCytomation, Glostrup, Denmark). Both LAM lung samples and kidney angiomyolipomas were stained by similar methods.

Results

GWAS analysis of S-LAM identifies two intergenic SNPs on chromosome 15

After multiple filtration steps and elimination of SNPs and samples as described in the Methods and shown in figure 1, GWAS was performed on 426 S-LAM subjects and 852 control subjects from the COPDGene project, for 5 426 936 SNPs (549 591 genotyped and 4 877 345 imputed) using CLR. 20 noncoding SNPs on chromosome 15 met genome-wide significance, of which two had been directly genotyped (rs4544201: p=4.19×10−8; rs2006950: p=6.12×10−9) (table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Statistical analyses of imputed single nucleotide polymorphisms (SNPs) with conditional logistic regression (CLR)

Quantile–quantile plots for CLRs and Manhattan plots demonstrated that the distribution of observed p-values met the expected distribution, with the exception of the 20 SNPs (figure 2), indicating that the analyses were free of systematic p-value inflation (genomic inflation factor 1.025). Scatter plots of PC scores indicated similarity between cases and controls in the discovery analyses (supplementary figure S2). All subjects from the COPDGene cohort were smokers and this might have caused an association between SNPs associated with nicotine addiction. We checked p-values for SNPs associated with nicotine addiction from the GWAS catalogue [36] and other SNPs correlated with those (r2>0.8) (supplementary table S2). None of those SNPs showed a significant difference in allele frequency in the LAM and COPDGene cohorts, indicating that our findings are not affected by nicotine addiction SNPs.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

a) Quantile–quantile and b) Manhattan plots for the discovery lymphangioleiomyomatosis (LAM) genome-wide association study using the imputed data. SNP: single nucleotide polymorphism. a) The observed distributions of p-values for 5 426 936 SNPs including 549 591 directly genotyped are plotted relative to the expected (null) distribution for the conditional logistic regression analysis. The grey shading indicates the 95% confidence interval for observed p-values relative to those expected. b) Manhattan plot. Each dot represents the p-value of a single SNP, plotted on the genome scale at the bottom. The y-axis value is the negative logarithm of the p-value for association between each genotyped SNP and sporadic LAM. Twenty SNPs on chromosome 15q met genome-wide significance.

Linkage disequilibrium blocks near genome-wide significant SNPs were identified using Haploview with default options [37]. All 20 SNPs, including the two directly genotyped, rs4544201 and rs2006950, belong to the same linkage disequilibrium block on 15q26.2; the latter two SNPs were 11 563 nucleotides apart and were strongly correlated (D′=0.977, r2=0.854) (supplementary figure S3). Based on the proximity of the two SNPs to each other and their linkage disequilibrium relationship, it is likely that there is a single disease susceptibility locus in the region. They are located in an intergenic gene desert between MCTP2 (multiple C2 and transmembrane domain containing 2; 1.1 Mb away) and NR2F2 (700 kb away) that contains many long noncoding RNAs (figure 3). Both SNPs have minor and major alleles of A and G, and showed a lower MAF in the S-LAM cohort than the control population. The ORs of a single minor allele in the S-LAM cohort were 0.49 and 0.47, respectively, in comparison with the control population (table 2). To adjust for the possible effect of the “winner's curse”, we used br2 [38], and found that the bias-adjusted ORs for rs4544201 and rs2006950 were 0.57 and 0.53, respectively.

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Genomic region on chromosome 15 containing the single nucleotide polymorphisms (SNPs) associated with lymphangioleiomyomatosis (LAM). CLR: conditional logistic regression. a) Ideogram of chromosome 15. b) 3 Mb region containing the SNPs associated with LAM. Manhattan plot at the top shows p-values for directly genotyped SNPs in this region, including the two SNPs meeting genome-wide significance (red dots). There are three protein-coding genes, NR2F2, MCTP2 and SPATA8, which are highlighted in yellow, and many long noncoding RNAs in this region. c) Expanded Manhattan plot of the 250 kb region showing both genotyped and imputed SNPs. SNP rs41374846, the candidate causal SNP, is indicated in purple and other SNPs are coloured according to their r2 value in relation to that SNP.

View this table:
  • View inline
  • View popup
TABLE 2

Genome-wide significant genotyped single nucleotide polymorphisms (SNPs)

We calculated the proportion of phenotypic variance explained by the genotyped SNPs, Embedded Image. Estimates of Embedded Image vary according to disease prevalence (supplementary figure S4). With prevalence set at 1 in 100 000 females, Embedded Image was 15% (0.3% on the observed 0–1 scale).

Given that TSC2 mutations occur consistently in LAM cells, genetic variants in each of TSC1 and TSC2 were considered a priori candidates for association with S-LAM. Hence, we checked SNPs within 1 Mb away from either gene. There were 566 and 416 SNPs for TSC1 and TSC2, respectively, and only rs11552431 (located at 16:1 823 024, 274 kb away from TSC2) was significant in CLR after Bonferroni correction at q<0.1 (nominal p=5.97×10−5). We included that SNP and nine others with the lowest p-values from these genes as covariates in the CLR. The significance of rs4544201 and rs2006950 changed minimally following this adjustment (supplementary table S3).

Replication analysis was performed for the two genome-wide significant and genotyped SNPs, which were genotyped in 196 additional non-Hispanic White S-LAM patients and compared with SNP allele frequencies in each of three control datasets: 1) 409 non-Hispanic White healthy COPDGene females who were not used for discovery analyses, 2) 1121 Hispanic White females from the MESA dataset [25, 39] and 3) 225 731 British White females in the UK Biobank dataset [26]. Similar ORs for association of the minor allele of these SNPs with S-LAM were observed in all three comparisons (table 2). Furthermore, we compared the MAFs of the two SNPs in LAM patients with those available from seven other studies (composed of non-Hispanic White European or USA populations), including all UK Biobank individuals. The MAFs of the two SNPs in LAM patients were significantly smaller than those reported in every other cohort (supplementary table S4).

To attempt to identify the causal SNP(s) among the SNPs with low p-values, we performed PICS analysis for all SNPs in table 1. rs41374846 had both significant association with LAM and the largest PICS probability (pPICS=0.65) (supplementary table S5), making it the candidate causal SNP in this association [23].

We also queried the GTEx database for SNPs in this linkage disequilibrium block that might have an eQTL relationship with expression levels of any gene. None were identified.

Association of GWAS-significant SNPs with NR2F2

The majority of SNPs associated with human disease or other phenotypes are thought to cause the association through effects on enhancer regions or other regulatory elements of a coding gene within the TAD containing the SNP [40]. To identify the TAD containing these SNPs, we used TAD information available for four tissues: IMR90 cells [41], lung tissue [42], H1-MSCs [43] and HUVECs [41]. Supplementary figures S5–S8 display Hi-C heatmaps for the 3 Mb region containing the GWAS SNPs and NR2F2 for these cells/tissues. HUGIn showed that p-values between rs4544201 and NR2F2 were <10−18 for IMR90 cells, <10−16 for H1-MSCs and ∼0.1 for lung tissue (not available for HUVECs) [28]. Thus, the region containing our significant SNPs interacts with the NR2F2 genomic region in IMR90 cells and H1-MSCs.

NR2F2 is the only protein-coding gene within the TAD containing the associated SNPs. This suggests that this SNP region may influence expression of NR2F2 as its mechanism of association with S-LAM.

To examine this possibility in further detail, we conducted gene-based analyses of association of SNPs within each of the three protein-coding genes in the 2 Mb region of chromosome 15 surrounding the GWAS SNPs using SKAT-O. NR2F2 was the only one of the three genes located in this chromosomal region that showed a significant association (p=0.03) (table 3).

View this table:
  • View inline
  • View popup
TABLE 3

Gene-based analyses of single nucleotide polymorphism (SNP) association with lymphangioleiomyomatosis (LAM)

NR2F2, also known as COUP-transcription factor II, encodes a member of the steroid/thyroid hormone superfamily of nuclear receptors [44] and plays important roles in many developmental processes, including the neural crest [45], which is considered a potential candidate cell of origin of LAM [46], as well as in lymphangiogenesis and in angiogenesis [47]. Hence, we considered it a potential target of regulation by one of the SNPs showing a strong association with LAM (table 2) and performed further studies.

Analysis of NR2F2 in kidney angiomyolipoma and LAM

Using RNA sequencing data, we compared the gene expression of four kidney angiomyolipomas and one abdominal LAM tumour with an extensive set of human cancers (from TCGA [32]) and normal tissues (from GTEx [29]) (figure 4). NR2F2 expression was higher in the LAM-related tumours than any TCGA cancer (figure 4a) and was also relatively highly expressed in LAM-related tumours in comparison with normal tissues (p=6.38×10−6, limma statistic) (figure 4b) [48]. In contrast, two other genes, SPATA8 (spermatogenesis associated 8) and MCTP2, that were next closest to the SNP region showing association with LAM (1.1 and 1.2 Mb distant) (figure 3b) had no expression in the LAM-related tumours (data not shown).

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Comparison of NR2F2 expression in kidney angiomyolipoma (ALM)/lymphangioleiomyomatosis (LAM) with a) cancer (The Cancer Genome Atlas (TCGA)) and b) normal (Gene and Tissue Expression (GTEx)) tissues. RSEM: RNA sequencing by expectation maximisation; RPKM: reads per kilobase per million mapped reads; EBV: Epstein–Barr virus. TCGA tumour abbreviations: KIRP: kidney renal papillary cell carcinoma; KIRC: kidney renal clear cell carcinoma; SARC: sarcoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; OV: ovarian serous cystadenocarcinoma; BRCA: breast invasive carcinoma; UCS: uterine carcinosarcoma; KICH: kidney chromophobe; UCEC: uterine corpus endometrial carcinoma; LIHC: liver hepatocellular carcinoma; SKCM: skin cutaneous melanoma; ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; MESO: mesothelioma; COAD: colon adenocarcinoma; LUAD: lung adenocarcinoma; THCA: thyroid carcinoma; READ: rectum adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; LUSC: lung squamous cell carcinoma; GBM: glioblastoma multiforme; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; HNSC: head and neck squamous cell carcinoma; LGG: low-grade glioma; DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; LAML: acute myeloid leukaemia. Box plot figures are shown to compare expression of NR2F2 a) in four angiomyolipoma tumours and one abdominal LAM lesion with 2463 cancers of 27 types (from TCGA) in RSEM units (the number of samples of each type is given in brackets), and b) with ∼7000 samples of 47 normal tissues (from GTEx) in RPKM units. Medians, interquartile ranges and 95% ranges are shown, with outliers indicated by circles.

Immunohistochemistry analysis also demonstrated strong nuclear expression of NR2F2 in both LAM lung sections (n=8) and kidney angiomyolipoma sections (n=4) (figure 5).

FIGURE 5
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5

Immunohistochemistry for NR2F2 in lymphangioleiomyomatosis (LAM) and kidney angiomyolipoma. Strong nuclear staining is seen in a) lung LAM cells and b) angiomyolipoma cells (brown stain). Some other cells also have nuclear staining for NR2F2, but most do not. Representative fields obtained from eight LAM lung samples and four angiomyolipoma samples examined by immunohistochemistry. Scale bar: 150 μm.

Discussion

LAM occurs almost exclusively in females of childbearing age. Most LAM patients who come to medical attention are sporadic cases without TSC and the origins of LAM in S-LAM patients are completely unknown. In the present study, we conducted a GWAS in a large cohort of S-LAM subjects. 20 intergenic SNPs were identified in a 34 kb linkage disequilibrium block on chromosome 15, which met genome-wide significance for association with LAM, including rs4544201 and rs2006950 that were directly genotyped (table 1). The association was replicated in a validation population.

The SNPs with association to S-LAM lie in a gene desert on distal chromosome 15q26.2. The nearest protein-coding gene is NR2F2, 700 kb away, and consideration of chromatin TADs in this region indicates that only NR2F2 is in/on the border of the TAD region containing the SNPs showing association with S-LAM in four relevant cells/tissues, suggesting that these SNP alleles may influence NR2F2 expression as the potential mechanism of their association with S-LAM development.

NR2F2 is an orphan nuclear receptor with known critical functions in development and tumorigenesis [49], making it a promising candidate driver gene in LAM pathogenesis. LAM occurs nearly exclusively in females, and oestrogen levels influence LAM development and progression [50, 51]. Small interfering RNA knockdown of oestrogen receptor α in MCF-7 breast cancer cells decreased NR2F2 expression, while treatment with oestradiol increased its expression [52]. This interaction between oestrogen receptor α and NR2F2 may also play a role in LAM development.

NR2F2 is highly expressed in LAM and angiomyolipoma by RNA sequencing analysis in comparison with large cancer and normal tissue datasets, and NR2F2 shows high expression with nuclear localisation in both LAM and angiomyolipoma by immunohistochemistry. Although we did not identify an eQTL relationship for any of the 20 SNPs associated with S-LAM for any gene in any normal tissue or cancer type [29], it is possible that such an eQTL relationship exists for LAM cells. We also note that the region of these SNPs contains several noncoding long RNAs, some antisense transcripts and microRNA miR1469 (figure 3b). It is possible that expression levels of one or more of these noncoding genes are affected by these SNP alleles and have a role in LAM development, a possibility which requires further investigation.

Lymphatic involvement in LAM is a hallmark pathological feature, with LAM cell clusters in the lung showing marked enrichment for lymphatic vessels [53, 54]. VEGF-D is a probable driver of lymphatic vessel growth in LAM, as serum VEGF-D level is increased in the majority of LAM patients, and serves as a diagnostic biomarker of LAM [55]. In mice, NR2F2 has been shown to be required, with SOX18 (SRY-box 18) for the polarised expression of PROX1 (Prospero homeobox) in a subset of endothelial cells within the cardinal vein at embryonic day 9.5, an event that leads to development of the lymphatic endothelium [56]. Hence, there is also a potential connection between NR2F2, VEGF-D, lymphatic development and LAM pathogenesis.

There are potential limitations to our study. Although our cohort of samples was large for a rare disease like S-LAM, it was of only moderate size for a GWAS. In order to obtain sufficient patient samples, we employed a worldwide recruitment strategy for S-LAM patients of European origin. Although our controls were all from the USA, they were selected for European ancestry to minimise population stratification issues. In addition, we employed EIGENSTRAT to remove genetic outliers from both S-LAM patients and controls. Finally, we used a CLR design, matching each case with two controls to further minimise confounding due to genetic heterogeneity. Previous studies have shown that CLR is superior to unconditional logistic regression if variables used for matching are true confounding variables and only a moderate number of controls are excluded through matching [57–63]. We also found that CLR generated more significant results than unconditional logistic regression (supplementary table S6). Functional analyses to confirm our hypothesis that NR2F2 is the gene affected by this SNP are limited due to the absence of a reliable LAM tumour cell line, the very low abundance of LAM cells in LAM lung specimens (often <5%) and lack of a LAM animal model.

In conclusion, our GWAS has identified noncoding SNPs on chromosome 15q26.2 whose alleles are associated with S-LAM, which are located in a TAD containing the orphan nuclear receptor NR2F2, suggesting a model in which these SNP alleles influence NR2F2 expression and thereby LAM pathogenesis. NR2F2 is relatively highly expressed in LAM and LAM-related tumours. NR2F2 has not previously been implicated in LAM, and these novel and unexpected findings will hopefully lead to a better understanding of the pathogenesis of this often progressive and lethal lung disorder.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material ERJ-00329-2019.Supplement

Acknowledgements

We thank all the LAM patients who participated in this research project and the following individuals who contributed to subject recruitment: Hubert Wirtz (Universitätsklinikum, Leipzig, Germany), Iris Bassi (LAM Italia, Pavia di Udine, Italy), Corine Durand (Association FLAM, Paris, France) Lesley Bogoslavski (Israeli LAM Organization, Jerusalem, Israel) and Mordechai Kramer (Beilinson Hospital, Petah Tikva, Israel). M.A. Pujana wishes to thank the Spanish Association of LAM (AELAM) for its support.

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Data and code availability: The primary GWAS and replication data will be made available on publication of this work through dbGaP (www.ncbi.nlm.nih.gov/gap).

  • Author contributions: Contributions to the conception and design of the work: S. Won, E.K. Silverman, G. Hunninghake and D.J. Kwiatkowski. Contributions to the acquisition, analysis or interpretation of data: all authors. Drafting the work or revising it critically for important intellectual content: all authors. Final approval of the version to be published: all authors. Agreement to be accountable for all aspects of the work: all authors.

  • Conflict of interest: W. Kim has nothing to disclose.

  • Conflict of interest: K. Giannikou has nothing to disclose.

  • Conflict of interest: J.R. Dreier has nothing to disclose.

  • Conflict of interest: S. Lee has nothing to disclose.

  • Conflict of interest: M.E. Tyburczy has nothing to disclose.

  • Conflict of interest: E.K. Silverman reports grants from NIH, during the conduct of the study; honoraria for symposium participation from Novartis; and grant and travel support from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: E Radzikowska has nothing to disclose.

  • Conflict of interest: S. Wu has nothing to disclose.

  • Conflict of interest: C-L. Wu has nothing to disclose.

  • Conflict of interest: E.P. Henske has nothing to disclose.

  • Conflict of interest: G. Hunninghake reports personal fees from Genentech, Boehringer Ingelheim, Gerson Lehrman Group and Mitsubishi Chemical, outside the submitted work.

  • Conflict of interest: H. Carel has nothing to disclose.

  • Conflict of interest: A. Roman has nothing to disclose.

  • Conflict of interest: M.A. Pujana reports grants from Roche Pharma outside the submitted work.

  • Conflict of interest: J. Moss has nothing to disclose.

  • Conflict of interest: S Won has nothing to disclose.

  • Conflict of interest: D.J. Kwiatkowski has nothing to disclose.

  • Support statement: This research was supported by the LAM Foundation, John Adler, The Engles Fund for TSC and LAM research, and the Bio-Synergy Research Project (NRF-2017M3A9C4065964) of the Ministry of Science, ICT and Future Planning through the Korean National Research Foundation and by the Intramural Research Program, National Institutes of Health, National Heart, Lung, and Blood Institute. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received November 27, 2018.
  • Accepted March 19, 2019.
  • The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2019
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Kitaichi M,
    2. Nishimura K,
    3. Itoh H, et al.
    Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151: 527–533.
    OpenUrlCrossRefPubMedWeb of Science
    1. Chu SC,
    2. Horiba K,
    3. Usuki J, et al.
    Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest J 1999; 115: 1041–1052.
    OpenUrl
    1. Urban T,
    2. Lazor R,
    3. Lacronique J, et al.
    Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Medicine 1999; 78: 321–337.
    OpenUrlCrossRefPubMed
    1. Cunha B,
    2. Conceição DM,
    3. Cabo C, et al.
    Pulmonary lymphangioleiomyomatosis on a post-menopausal woman with chronic lymphocytic leukaemia. Case Rep Clin Med 2016; 5: 101–104.
    OpenUrl
  2. ↵
    1. Youssef AL,
    2. Alami B,
    3. Sahnoun F, et al.
    Lymphangioleiomyomatosis: an unusual age of diagnosis with literature review. Int J Diagn Imaging 2014; 1: 17–20.
    OpenUrl
  3. ↵
    1. Soler-Ferrer C,
    2. Gómez-Lozano A,
    3. Clemente-Andrés C, et al.
    Lymphangioleiomyomatosis in a post-menopausal women. Arch Bronconeumol 2010; 46: 148–150.
    OpenUrlPubMed
  4. ↵
    1. Taylor JR,
    2. Ryu J,
    3. Colby TV, et al.
    Lymphangioleiomyomatosis. N Engl J Med 1990; 323: 1254–1260.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Kalassian KG,
    2. Doyle R,
    3. Kao P, et al.
    Lymphangioleiomyomatosis: new insights. Am J Respir Crit Care Med 1997; 155: 1183–1186.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Giannikou K,
    2. Malinowska IA,
    3. Pugh TJ, et al.
    Whole exome sequencing identifies TSC1/TSC2 biallelic loss as the primary and sufficient driver event for renal angiomyolipoma development. PLoS Genet 2016; 12: e1006242.
    OpenUrlCrossRef
  7. ↵
    1. Carsillo T,
    2. Astrinidis A,
    3. Henske EP
    . Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085–6090.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Regan EA,
    2. Hokanson JE,
    3. Murphy JR, et al.
    Genetic epidemiology of COPD (COPDGene) study design. COPD 2011; 7: 32–43.
    OpenUrlWeb of Science
  9. ↵
    1. Purcell S,
    2. Neale B,
    3. Todd-Brown K, et al.
    PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Song YE,
    2. Lee S,
    3. Park K, et al.
    ONETOOL for the analysis of family-based big data. Bioinformatics 2018; 34: 2851–2853.
    OpenUrl
  11. ↵
    1. Wigginton JE,
    2. Cutler DJ,
    3. Abecasis GR
    . A note on exact tests of Hardy–Weinberg equilibrium. Am J Hum Genet 2005; 76: 887–893.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Raymond M,
    2. Rousset F
    . An exact test for population differentiation. Evolution 1995; 49: 1280–1283.
    OpenUrlCrossRefWeb of Science
  13. ↵
    1. McCarthy S,
    2. Das S,
    3. Kretzschmar
    W, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 2016; 48: 1279–1283.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Loh P-R,
    2. Danecek P,
    3. Palamara PF, et al.
    Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet 2016; 48: 1443–1448.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Durbin R
    . Efficient haplotype matching and storage using the positional Burrows–Wheeler transform (PBWT). Bioinformatics 2014; 30: 1266–1272.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Marchini J,
    2. Howie B
    . Genotype imputation for genome-wide association studies. Nat Rev Genet 2010; 11: 499–511.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Price AL,
    2. Patterson NJ,
    3. Plenge RM, et al.
    Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904–909.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Sekhon JS
    . Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2011; 42: 1–52.
    OpenUrl
  19. ↵
    1. Therneau TM,
    2. Lumley T
    . Package “survival”. 2017. https://CRAN.R-project.org/package=survival Date last accessed: April 4, 2019.
  20. ↵
    1. Farh KK-H,
    2. Marson A,
    3. Zhu J, et al.
    Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015; 518: 337–343.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Lee S,
    2. Emond MJ,
    3. Bamshad MJ, et al.
    Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet 2012; 91: 224–237.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Bild DE,
    2. Bluemke DA,
    3. Burke GL, et al.
    Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156: 871–881.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Sudlow C,
    2. Gallacher J,
    3. Allen N, et al.
    UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12: e1001779.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Dixon JR,
    2. Selvaraj S,
    3. Yue F, et al.
    Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 2012; 485: 376–380.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Martin JS,
    2. Xu Z,
    3. Reiner AP, et al.
    HUGIn: Hi-C unifying genomic interrogator. Bioinformatics 2017; 33: 3793–3795.
    OpenUrl
  26. ↵
    1. Lonsdale J,
    2. Thomas J,
    3. Salvatore M, et al.
    The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580–585.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Kim D,
    2. Pertea G,
    3. Trapnell C, et al.
    TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Li B,
    2. Dewey CN
    . RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011; 12: 323.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Cancer Genome Atlas Research Network
    . Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061–1068.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Ongen H,
    2. Buil A,
    3. Brown AA, et al.
    Fast and efficient QTL mapper for thousands of molecular phenotypes. Bioinformatics 2015; 32: 1479–1485.
    OpenUrl
  31. ↵
    1. Stegle O,
    2. Parts L,
    3. Durbin R, et al.
    A Bayesian framework to account for complex non-genetic factors in gene expression levels greatly increases power in eQTL studies. PLoS Comput Biol 2010; 6: e1000770.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Bongaarts A,
    2. Giannikou K,
    3. Reinten RJ, et al.
    Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget 2017; 8: 95516–95529.
    OpenUrl
  33. ↵
    1. MacArthur J,
    2. Bowler E,
    3. Cerezo M, et al.
    The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res 2016; 45: D896–D901.
    OpenUrl
  34. ↵
    1. Barrett JC,
    2. Fry B,
    3. Maller J, et al.
    Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2004; 21: 263–265.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Poirier JG,
    2. Faye LL,
    3. Dimitromanolakis A, et al.
    Resampling to address the winner's curse in genetic association analysis of time to event. Genet Epidemiol 2015; 39: 518–528.
    OpenUrl
  36. ↵
    1. Hankinson JL,
    2. Kawut SM,
    3. Shahar E, et al.
    Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Chest 2010; 137: 138–145.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Grubert F,
    2. Zaugg JB,
    3. Kasowski M, et al.
    Genetic control of chromatin states in humans involves local and distal chromosomal interactions. Cell 2015; 162: 1051–1065.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Rao SS,
    2. Huntley MH,
    3. Durand NC, et al.
    A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 2014; 159: 1665–1680.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Schmitt AD,
    2. Hu M,
    3. Jung I, et al.
    A compendium of chromatin contact maps reveals spatially active regions in the human genome. Cell Rep 2016; 17: 2042–2059.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Dixon JR,
    2. Jung I,
    3. Selvaraj S, et al.
    Chromatin architecture reorganization during stem cell differentiation. Nature 2015; 518: 331–336.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Qiu Y,
    2. Krishnan V,
    3. Zeng Z, et al.
    Isolation, characterization, and chromosomal localization of mouse and human COUP-TF I and II genes. Genomics 1995; 29: 240–246.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Rada-Iglesias A,
    2. Bajpai R,
    3. Prescott S, et al.
    Epigenomic annotation of enhancers predicts transcriptional regulators of human neural crest. Cell Stem Cell 2012; 11: 633–648.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Julian LM,
    2. Delaney SP,
    3. Wang Y, et al.
    Human pluripotent stem cell-derived TSC2-haploinsufficient smooth muscle cells recapitulate features of lymphangioleiomyomatosis. Cancer Res 2017; 77: 5491–5502.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Qin J,
    2. Chen XP,
    3. Xie X, et al.
    COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107: 3687–3692.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Ritchie ME,
    2. Phipson B,
    3. Wu D, et al.
    limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Xu MF,
    2. Qin J,
    3. Tsai SY, et al.
    The role of the orphan nuclear receptor COUP-TFII in tumorigenesis. Acta Pharmacol Sin 2015; 36: 32–36.
    OpenUrl
  47. ↵
    1. Juvet SC,
    2. Hwang D,
    3. Downey GP
    . Rare lung diseases I – lymphangioleiomyomatosis. Can Respir J 2006; 13: 375–380.
    OpenUrlPubMed
  48. ↵
    1. McCormack FX,
    2. Gupta N,
    3. Finlay GR, et al.
    Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med 2016; 194: 748–761.
    OpenUrl
  49. ↵
    1. Riggs KA,
    2. Wickramasinghe NS,
    3. Cochrum RK, et al.
    Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Cancer Res 2006; 66: 10188–10198.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Glasgow CG,
    2. Taveira-DaSilva AM,
    3. Darling TN, et al.
    Lymphatic involvement in lymphangioleiomyomatosis. Ann NY Acad Sci 2008; 1131: 206–214.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Seyama K,
    2. Mitani K,
    3. Kumasaka T
    . Lymphangioleiomyoma cells and lymphatic endothelial cells expression of VEGFR-3 in lymphangioleiomyoma cell clusters. Am J Pathol 2010; 176: 2051–2052.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Young LR,
    2. Lee HS,
    3. Inoue Y, et al.
    Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1: 445–452.
    OpenUrl
  53. ↵
    1. Srinivasan RS,
    2. Geng X,
    3. Yang Y, et al.
    The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev 2010; 24: 696–707.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Breslow N,
    2. Day N,
    3. Halvorsen K, et al.
    Estimation of multiple relative risk functions in matched case-control studies. Am J Epidemiol 1978; 108: 299–307.
    OpenUrlPubMedWeb of Science
    1. Kupper LL,
    2. Karon JM,
    3. Kleinbaum DG, et al.
    Matching in epidemiologic studies: validity and efficiency considerations. Biometrics 1981; 37: 271–291.
    OpenUrlCrossRefPubMedWeb of Science
    1. McKinlay SM
    . Pair-matching – a reappraisal of a popular technique. Biometrics 1977; 33: 725–735.
    OpenUrlCrossRefPubMedWeb of Science
    1. Thompson WD,
    2. Kelsey JL,
    3. Walter SD
    . Cost and efficiency in the choice of matched and unmatched case-control study designs. Am J Epidemiol 1982; 116: 840–851.
    OpenUrlPubMedWeb of Science
    1. Thomas DC,
    2. Greenland S
    . The relative efficiencies of matched and independent sample designs for case-control studies. J Chronic Dis 1983; 36: 685–697.
    OpenUrlCrossRefPubMedWeb of Science
    1. Miettinen OS
    . Estimation of relative risk from individually matched series. Biometrics 1970; 26: 75–86.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Luca D,
    2. Ringquist S,
    3. Klei L, et al.
    On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am J Hum Genet 2008; 82: 453–463.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 53 Issue 6 Table of Contents
European Respiratory Journal: 53 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis
Wonji Kim, Krinio Giannikou, John R. Dreier, Sanghun Lee, Magdalena E. Tyburczy, Edwin K. Silverman, Elżbieta Radzikowska, Shulin Wu, Chin-Lee Wu, Elizabeth P. Henske, Gary Hunninghake, Havi Carel, Antonio Roman, Miquel Angel Pujana, Joel Moss, Sungho Won, David J. Kwiatkowski
European Respiratory Journal Jun 2019, 53 (6) 1900329; DOI: 10.1183/13993003.00329-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis
Wonji Kim, Krinio Giannikou, John R. Dreier, Sanghun Lee, Magdalena E. Tyburczy, Edwin K. Silverman, Elżbieta Radzikowska, Shulin Wu, Chin-Lee Wu, Elizabeth P. Henske, Gary Hunninghake, Havi Carel, Antonio Roman, Miquel Angel Pujana, Joel Moss, Sungho Won, David J. Kwiatkowski
European Respiratory Journal Jun 2019, 53 (6) 1900329; DOI: 10.1183/13993003.00329-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Systematic assessment of respiratory health in illness susceptible athletes
  • Identifying early PAH biomarkers in systemic sclerosis
  • Viable virus aerosol propagation by PAP circuit leak
Show more Original Articles

Interstitial lung disease and rare lung disease

  • Transcriptomics of BAL cells identifies molecular endotypes of sarcoidosis
  • FEV1 and DLCO as indicators for therapy in premenopausal LAM patients
Show more Interstitial lung disease and rare lung disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society